EMPA-REG OUTCOME
2015
Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes
In 7,020 patients with type 2 diabetes and cardiovascular disease, empagliflozin reduced cardiovascular death compared with placebo.
Result
Efficacy: CV death, MI or strokeHR 0.86
Below 1 favours empagliflozin, above 1 favours placebo.
Also reported: CV death down 38 %; HF hospitalisation down 35 %.
- Subtopic
- SGLT2 inhibitors
- Design
- Double-blind RCT
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- ESC 2024 CCSESC 2021 PreventionESC 2023 DiabetesACC/AHA 2023 CCDACC/AHA 2019 Primary PreventionACC/AHA 2024 PADACC/AHA 2026 CKM
- Source
- Zinman B, et al. N Engl J Med. 2015;373(22):2117-2128.doi 10.1056/NEJMoa1504720
Discussion & critique
First cardiovascular-outcomes trial to show an SGLT2-inhibitor benefit, unexpectedly driven by heart failure and CV death, launching the SGLT2i era.